Literature DB >> 32418775

Tyrophagus putrescentiae group 4 allergen allergenicity and epitope prediction.

F-X Teng1, H-F Huang2, D-Z Ge3, L-L Yu1, C Xu3, Y-B Cui4.   

Abstract

INTRODUCTION AND
OBJECTIVES: Allergen-specific immunotherapy (ASIT) is the only allergic disease-modifying therapy available for children and adults, and recombinant allergens are an interesting approach to improve allergy diagnosis and ASIT. Tyrophagus putrescentiae is a common storage mite that produces potent allergens. The aim of this study was to express and characterize recombinant group 4 allergen protein of T. putrescentiae (Tyr p 4), and to further investigate allergenicity and potential epitopes of Tyr p 4.
MATERIALS AND METHODS: The cDNA encoding Tyr p 4 was generated by RT-PCR and subcloned into pET-28a(+) plasmid. The plasmid was then transformed into E. coli cells for expression. After purification by nickel affinity chromatography and identification by SDS-PAGE, recombinant Tyr p 4 protein was used for a skin prick test and an ELISA to determine the allergic response.
RESULTS: Study participants' allergic response rate to Tyr p 4 protein was 13.3% (16/120). Eight B-cell epitopes and three T-cell epitopes of Tyr p 4 were predicted.
CONCLUSIONS: Similar to group 4 allergens of other species of mite, allergenicity of Tyr p 4 is weak. The expression, characterization and epitope prediction of recombinant Tyr p 4 protein provide a foundation for further study of this allergen in the diagnosis and ASIT of storage mite allergy.
Copyright © 2020 SEICAP. Published by Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Homology modeling; Immunoglobulin E (IgE); Molecular cloning; Recombinant mite allergen; Storage mites

Year:  2020        PMID: 32418775     DOI: 10.1016/j.aller.2020.02.006

Source DB:  PubMed          Journal:  Allergol Immunopathol (Madr)        ISSN: 0301-0546            Impact factor:   1.667


  1 in total

1.  Expression, epitope prediction and IgE-binding of the Tyrophagus putrescentiae group 13 allergen.

Authors:  Nan Wang; Ying Zhou; Meili Wu; Hanting Zhu; Yubao Cui
Journal:  Exp Ther Med       Date:  2020-08-27       Impact factor: 2.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.